| SGK3 - Serum/Glucocorticoid Regulated Kinase 3 | |
|---|---|
| Symbol | SGK3 |
| Full Name | Serum/Glucocorticoid Regulated Kinase 3 |
| Chromosome | 8q12.3 |
| NCBI Gene ID | [27347](https://www.ncbi.nlm.nih.gov/gene/27347) |
| OMIM | [607591](https://www.omim.org/entry/607591) |
| Ensembl | [ENSG00000115297](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000115297) |
| UniProt | [Q9Y2M5](https://www.uniprot.org/uniprot/Q9Y2M5) |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Cancer, Neutropenia |
SGK3 (Serum/Glucocorticoid Regulated Kinase 3) is a serine/threonine protein kinase that belongs to the SGK family, which also includes SGK1 and SGK2. While SGK1 and SGK2 are widely studied, SGK3 has emerged as a critical regulator of neuronal signaling, particularly in the PI3K/AKT/mTOR pathway and autophagy [1].
SGK3 is characterized by a unique N-terminal domain containing a phox homology (PX) domain that targets the protein to endosomal membranes, where it regulates vesicular trafficking and lysosomal function [2]. This subcellular localization distinguishes SGK3 from other SGK family members and is particularly relevant to neurodegenerative disease mechanisms, where lysosomal dysfunction plays a central role.
The SGK3 gene spans approximately 35 kb on chromosome 8q12.3 and consists of 14 exons encoding a 644-amino acid protein. The gene shares structural similarity with SGK1 and SGK2, particularly in the catalytic domain, but possesses the distinctive N-terminal PX domain that mediates membrane association [3]. This domain binds to phosphatidylinositol-3-phosphate (PI3P) on endosomal membranes, targeting SGK3 to the vesicular compartment where it participates in trafficking and signaling.
SGK3 functions as a downstream effector of PI3K signaling, similar to AKT1 but with distinct substrate specificity and cellular functions. The kinase is activated by PDK1-mediated phosphorylation at Thr320, a site conserved across SGK family members [4]. Additionally, SGK3 can be activated by mTORC2-mediated phosphorylation, linking it to both growth factor and nutrient signaling pathways.
Key SGK3 substrates in neurons include:
SGK3 participates in multiple critical neuronal signaling cascades:
PI3K/AKT pathway: SGK3 is activated downstream of PI3K and can phosphorylate many of the same substrates as AKT, including FOXO transcription factors and glycogen synthase kinase 3 beta (GSK3B) [6]. However, SGK3 has distinct temporal and spatial regulation, suggesting non-redundant functions.
mTOR pathway: SGK3 interacts with the mTOR signaling network through multiple mechanisms. mTORC2 can phosphorylate and activate SGK3, while SGK3 in turn regulates mTORC1 lysosomal recruitment and activation [2]. This places SGK3 at a critical node integrating growth factor signals with nutrient sensing.
Autophagy: SGK3 plays an important role in regulating autophagy through its effects on lysosomal function and the ULK1 complex. By promoting lysosomal trafficking and mTORC1 signaling, SGK3 influences the balance between protein synthesis and degradation [7].
Key interacting partners of SGK3 include:
| Partner | Interaction Type | Function |
|---|---|---|
| PDK1 | Phosphorylation | Activation at Thr320 |
| AKT1 | Parallel signaling | Shared substrates |
| MTOR | Complex formation | mTORC2 activation |
| ULK1 | Regulation | Autophagy initiation |
| RAGA/B/D | GTPase binding | mTORC1 regulation |
| ATG14 | Autophagy regulation | Autophagosome formation |
SGK3 exhibits broad expression throughout the brain with highest levels in regions associated with learning and memory:
In neurons, SGK3 localizes to dendritic compartments and synaptic terminals, where it regulates synaptic plasticity and neurotransmission. The endosomal localization of SGK3 is particularly evident in axons and presynaptic terminals, consistent with its role in vesicular trafficking [8].
SGK3 has emerged as a significant player in Alzheimer's disease pathogenesis through multiple mechanisms:
Tau phosphorylation: SGK3 can phosphorylate tau protein at sites including Thr181 and Ser396, which are also targeted by GSK3B [5]. Dysregulated SGK3 activity may contribute to tau hyperphosphorylation and neurofibrillary tangle formation.
mTOR dysregulation: Altered SGK3 signaling contributes to the mTOR hyperactivation observed in AD brains, leading to impaired autophagy and accumulation of damaged proteins [9].
Synaptic dysfunction: SGK3 regulates synaptic proteins involved in learning and memory, and its dysregulation may contribute to cognitive decline.
Neuroinflammation: SGK3 influences inflammatory responses in microglia and astrocytes through NF-κB signaling pathways [10].
Mouse models lacking SGK3 show enhanced tau pathology and memory deficits, supporting a protective role for SGK3 in AD [4].
In Parkinson's disease, SGK3 is implicated in:
Dopaminergic neuron survival: SGK3 activity supports the survival of dopaminergic neurons in the substantia nigra. Genetic studies have identified SGK3 variants associated with PD risk [11].
Autophagy and mitophagy: SGK3 regulates autophagy of damaged mitochondria (mitophagy), a process critical for maintaining neuronal health. Impaired SGK3 signaling may contribute to mitochondrial dysfunction in PD [7].
α-Synuclein clearance: Through its effects on lysosomal function, SGK3 influences the clearance of alpha-synuclein, whose aggregation is a hallmark of PD pathology.
Conditional knockout of SGK3 in dopaminergic neurons produces progressive parkinsonism in mice, including motor deficits and loss of substantia nigra neurons [12].
Beyond neurodegeneration, SGK3 was originally identified as an oncogene. Activating mutations and overexpression of SGK3 are found in several cancers, particularly those with hyperactive PI3K signaling. The dual role of SGK3 in both cancer and neurodegeneration presents challenges for therapeutic targeting.
Targeting SGK3 signaling offers therapeutic potential for neurodegenerative diseases, though selectivity challenges exist:
| Approach | Strategy | Status |
|---|---|---|
| mTOR inhibitors | Rapamycin, everolimus | Clinical trials for AD/PD |
| SGK3 inhibitors | Small molecule inhibitors | Preclinical |
| Autophagy enhancers | Trehalose, lithium | Investigational |
| Gene therapy | AAV-SGK3 expression | Preclinical |
The challenge with SGK3 inhibition is the potential for enhancing tumor growth, suggesting that tissue-specific or conditional approaches may be necessary [13]. An alternative strategy involves targeting downstream effectors like mTOR or ULK1 that mediate SGK3's neuronal effects while sparing its oncogenic functions.
Key open questions about SGK3 in neurodegeneration include: